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Is paliperidone palmitate more effective than other
long-acting injectable antipsychotics?
R. Patel1*, E. Chesney1, M. Taylor1, D. Taylor2,3 and P. McGuire1
1Department of Psychosis Studies, King’s College London, Institute of Psychiatry, Psychology & Neuroscience, Box PO 63, De Crespigny Park,
Denmark Hill, London, UK
2Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK
3King’s College London, Institute of Pharmaceutical Science, 5th Floor, Franklin-Wilkins Building, 150 Stamford Street, London, UK
Background. Paliperidone palmitate is one of the most widely prescribed long-acting injectable (LAI) antipsychotics in
the UK. However, it is relatively expensive and there are few data comparing its effectiveness to that of other LAI anti-
psychotics. We sought to address this issue by analyzing a large anonymized electronic health record (EHR) dataset from
patients treated with LAI antipsychotics.
Methods. EHR data were obtained from 1281 patients in the South London and Maudsley NHS Foundation Trust
(SLaM) who started treatment with a LAI antipsychotic between 1 April 2011 and 31 January 2015. The number of
days spent as a psychiatric inpatient and the number of admissions to a psychiatric hospital were analyzed in each of
the 3 years before and after LAI prescription.
Results. Patients treated with paliperidone palmitate (n = 430; 33.6%) had a greater number of inpatient days and a
greater number of admissions in the year prior to treatment than those treated with other LAI antipsychotics.
Nevertheless, in the 3 years after initiation there were no signiﬁcant differences between paliperidone and the other
LAI antipsychotics in the number of days as an inpatient (B coefﬁcient 5.4 days, 95% conﬁdence interval (CI) −57.3
to 68.2, p = 0.86) or number of hospital admissions (Incidence rate ratio 1.07, 95% CI 0.62 to 1.83, p = 0.82).
Conclusion. Paliperidone palmitate was more likely to be prescribed in patients with more frequent and lengthy hos-
pital admissions prior to initiation. However, the absence of differences in outcomes after initiation indicates that pali-
peridone palmitate was not more effective than other cheaper LAI antipsychotics.
Received 12 January 2017; Revised 13 September 2017; Accepted 14 September 2017
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Introduction
One of the key factors that limits the clinical effective-
ness of treatment of psychotic disorders with oral anti-
psychotic medication is poor adherence. Although
long-acting injectable (LAI) antipsychotics may pro-
vide a means of overcoming this problem (Tiihonen
et al. 2011; Marcus et al. 2015), a minority of patients
prescribed antipsychotics (typically about 12% of the
population investigated in the present study) (Pinto
et al. 2010) are treated with LAIs. This may reﬂect
patients being less willing to be treated via an intra-
muscular injection, and concerns about stigmatization,
adverse effects and limiting patient autonomy
(Johnson, 2009), concerns that may be shared by the
prescribing clinician. In practice, LAIs are typically
used in patients that require chronic treatment, who
have a history of poor treatment adherence, frequent
relapses or hospital admissions. Until relatively
recently, the use of LAIs was in decline, but the advent
of second-generation LAIs, which may have fewer
adverse effects, has led to calls for their more wide-
spread use (Barnes, 2005; Brissos et al. 2014; Bosanac
& Castle, 2015).
A meta-analysis of randomized controlled trials
(RCTs) comparing oral and LAI antipsychotics found
no difference in risk of relapse in patients with schizo-
phrenia (Kishimoto et al. 2014). On the other hand, a
meta-analysis of mirror-image studies, where periods
of oral and LAI antipsychotic in the same patients
are compared, showed that LAIs reduced the relative
risk of hospitalization by half (Kishimoto et al. 2013).
These apparently conﬂicting ﬁndings may reﬂect an
effect of study design that is particular to LAIs
(Kirson et al. 2013). A review comparing different
study designs to evaluate outcomes associated with
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LAIs (Haddad et al. 2015) found that two recent RCTs,
which had a pragmatic design (Alphs et al. 2015;
Schreiner et al. 2015) demonstrated better outcomes
with paliperidone palmitate compared with oral anti-
psychotics. The main advantage of treatment with
LAIs as opposed to oral antipsychotics is improved
treatment adherence, but this beneﬁt may be dimin-
ished in controlled trials: when a patient is taking
part in a trial they may be more likely to take oral
medication than in routine clinical care, and their
adherence in a trial will usually be more closely
monitored.
Second-generation antipsychotics may have fewer
adverse effects than ﬁrst-generation antipsychotics
(Leucht et al. 2009), which may lead to the improved
adherence, and a reduced risk of relapse and hospital
admission (Leucht et al. 2011). At present, there are
four second-generation LAIs licensed for clinical use:
risperidone, olanzapine pamoate or embonate, aripi-
prazole and paliperidone palmitate. Paliperidone
palmitate was introduced in the UK in 2011 and is
the LAI formulation of oral paliperidone. In 2015,
5.0% of all community LAI prescriptions in the UK
were for paliperidone palmitate, though due to its
high cost it accounted for 25.1% of all spending on
LAI antipsychotics (Health and Social Care
Information Centre, 2005). This has led to an ongoing
debate about the cost-effectiveness of treatment with
the drug. In comparison with placebo, paliperidone
is effective at reducing psychotic symptoms(Kramer
et al. 2010; Alphs et al. 2011) and the risk of relapse
and hospitalization (Hough et al. 2010; Kozma et al.
2011; Berwaerts et al. 2015), and is generally well toler-
ated (Coppola et al. 2012). In comparison with seven
different oral antipsychotics in a single open-label
trial, paliperidone palmitate was associated with a
lower rate of treatment failure (40% v. 54%) at 15
months (Alphs et al. 2015). The only comparison
between oral paliperidone and injectable paliperidone
palmitate was made by comparing the results of two
separate, but similarly designed placebo-controlled
trials (Kramer et al. 2007; Hough et al. 2010). Here the
injectable preparation was associated with a signiﬁ-
cantly lower risk of relapse (Markowitz et al. 2013).
To date, data comparing the efﬁcacy of paliperidone
palmitate with that of other LAIs in head to head clin-
ical trials is sparse. In a study of 311 participants fol-
lowed up for up to 24 months (which was not
sponsored by the manufacturer), the efﬁcacy of pali-
peridone palmitate was found to be no different to
haloperidol decanoate (McEvoy et al. 2014).
Compared to risperidone LAI, two studies (sponsored
by the manufacturers of paliperidone palmitate) with
13 weeks of follow-up of 452 and 1220 participants,
respectively found that paliperidone palmitate was
non-inferior (Li et al. 2011; Pandina et al. 2011), but
another study of 749 acutely symptomatic patients fol-
lowed up for 53 weeks reported that it was less effect-
ive (Fleischhacker et al. 2012). In a study (sponsored by
the manufacturers of aripiprazole LAI) of 295 partici-
pants followed up for 28 weeks, paliperidone palmi-
tate has been shown to be inferior compared to
aripiprazole LAI (Naber et al. 2015). Together, these
studies suggest that paliperidone is effective, but not
necessarily more effective than another second-
generation LAIs. This limited evidence from clinical
trials seems unlikely to account for the increasing
popularity of the drug among prescribers. We sought
to assess the effectiveness of paliperidone relative to
other LAIs in a large sample that is more representa-
tive of the population of patients that are seen in clin-
ical practice than those recruited to controlled
treatment trials. We also conducted an audit of senior
psychiatrists within the same mental healthcare service
to better understand the rationale for choosing to pre-
scribe paliperidone palmitate.
Method
Study setting and participants
The study was conducted using clinical data collected
from patients receiving mental healthcare from the
South London and Maudsley NHS Foundation Trust
(SLaM). SLaM provides inpatient and community ser-
vices for a catchment population of around 1.5 million
people living in southeast London. We included
patients aged between 16 and 65 years who had been
started on a LAI between 1 April 2011 and 31
January 2015. This time period was chosen because
paliperidone palmitate ﬁrst became locally available
on 1 April 2011. LAI medications were deﬁned as
any LAI antipsychotic listed in chapter 4.2.2 of the
British National Formulary between 1 April 2011 and
31 January 2015. These were aripiprazole, ﬂupentixol
decanoate, ﬂuphenazine decanoate, haloperidol, olan-
zapine embonate, paliperidone palmitate, pipotiazine
palmitate, risperidone and zuclopenthixol decanoate
(but not zuclopenthixol acetate). Using these criteria,
data from 1281 people were available for analysis.
Source of clinical data
Clinical data were obtained from the SLaM Biomedical
Research Centre (BRC) Case Register, which contains
anonymized electronic health records (EHRs) of over
270 000 patients. The clinical information documented
includes structured ﬁelds (for demographic informa-
tion) and de-identiﬁed unstructured free text ﬁelds
from case notes and correspondence. Data were
obtained from structured and unstructured clinical
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records using the Clinical Record Interactive Search
tool (CRIS). CRIS is a bespoke database search and
assembly tool that has supported a range of studies
using clinical data from the SLaM BRC Case Register
(Patel et al. 2015a, 2015b, 2015c, 2015d, 2016a, 2016b).
Ethical approval
The SLaM BRC Case Register and CRIS have received
ethical approval from the Oxfordshire Research Ethics
Committee C (08/H0606/71+5) as an anonymized data-
set for mental health research. A patient-led oversight
committee provides governance for all projects con-
ducted using these data. Any researcher wishing to
use CRIS for a research study must undergo a rigorous
approval procedure in accordance with UK
Department of Health standards. A robust ﬁrewall and
data security framework governs access to clinical data
from the case register and only approved researchers
are permitted to access data from the case register.
Exposure
The exposure was deﬁned as the ﬁrst antipsychotic
LAI medication prescribed to each patient included
in the study. Clinical outcomes were measured after
an index date deﬁned as the date of the ﬁrst prescrip-
tion of the LAI plus 1 month. This deﬁnition was cho-
sen to allow for adequate time for peak plasma levels
of antipsychotic to be reached and to ensure that the
exposure always occurred prior to measurement of
clinical outcome measures.
Clinical outcome measures
The primary outcome measure was the number of days
spent as an inpatient in a psychiatric hospital in each of
the three years before and after the index date. This
was chosen because it represents an important meas-
ure of the burden of illness for individual patients,
their family and carers, and mental healthcare services.
It is also a key factor that determines the economic cost
of mental health care (McCrone et al. 2008). The sec-
ondary outcome measure was the number of admis-
sions to a psychiatric hospital in SLaM in each of the
three years before and after the index date. Outcome
data were collected up to 28 February 2015. Of the
1281 patients in the study, 980 had outcome data avail-
able at 1 year (i.e. index date prior to 28 February
2014), 623 at 2 years (i.e. index date prior to 28
January 2013) and 268 at 3 years (i.e. index date prior
to 28 January 2012).
Covariates
The following variables were extracted as categorical
covariates for multivariable analyses: age, gender,
ethnicity, marital status, diagnosis, borough of resi-
dence and whether started on LAI as an inpatient.
The number of hospital admissions in the 3 years
prior to the index date was extracted as a continuous
covariate as a measure of illness severity. All categor-
ical covariate data obtained were those recorded clos-
est to the index date. Ethnicity was recorded
according to categories deﬁned by the UK Ofﬁce for
National Statistics. Marital status was recorded in the
following categories: married or cohabiting; divorced
or separated; single; unknown. Diagnosis of a
psychotic disorder was deﬁned according to ICD-10
and included schizophrenia or related disorders
[schizophrenia (F20), delusional disorder (F22),
schizophrenia-like disorders (F23, F28, F29)], schizo-
affective disorder (F25), mania or bipolar disorder
(F30, F31), psychotic depression (F32.3, F33.3),
drug-induced psychosis (F1x.5) and any other psych-
otic disorder not otherwise speciﬁed.
Statistical analysis
Stata (version 12.0) was used to analyze the data.
Descriptive statistics for the exposure, outcome and
covariate variables were obtained as frequencies and
percentages for categorical variables and means and
standard deviations for continuous variables. The asso-
ciation of starting paliperidone palmitate v. other anti-
psychotic LAIs was tested in the following analyses:
(i) Demographic and clinical covariates using multi-
variable binary logistic regression;
(ii) Number of days spent in hospital using multiple
linear regression;
(iii) Number of hospital admissions using multivari-
able negative binomial regression.
Where missing data were present in covariate data
(58 patients with no known marital status), the missing
data category was included as a predictor variable in
regression analyses.
Audit of prescribers
A survey of Consultant Psychiatrists practising in
SLaM was conducted to assess their views on LAI anti-
psychotic prescribing. The psychiatrists were invited to
complete the survey which asked three questions:
(i) Which LAI antipsychotics do you prescribe
regularly?
(ii) Which LAI antipsychotic would you choose to
receive yourself?
(iii) If paliperidone LAI were no longer available to
prescribe, would this be a good/neutral/bad thing?
The psychiatrists were also invited to provide free
text comments on their responses to the questions.
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Results
LAI antipsychotic exposure
Table 1 shows the breakdown of the different LAIs that
were prescribed. Paliperidone palmitate was the most
frequently prescribed LAI and 430 patients (33.6%)
were treated with this drug. Compared with other
LAIs, patients treated with paliperidone palmitate
were more likely to have started treatment in hospital
than in outpatient services, and were more likely to
be female (Table 2).
Clinical outcomes
Figure 1 shows the mean number of days spent in a
psychiatric hospital, and Fig. 2 the mean number of
admissions to a psychiatric hospital in the 3 years
before and after the index date for each antipsychotic
LAI, where data of more than 10 patients were avail-
able. Full data are presented in the Supplementary
Material: eTables 1 and 2. In the year prior to the
index date, patients prescribed paliperidone palmitate
(n = 430) had a signiﬁcantly greater number of
inpatient days (β coefﬁcient 12.3 days, 95% conﬁdence
interval (CI) 2.3 to 19.2, p = 0.001) and greater number
of admissions (IRR 1.44, 95% CI 1.29 to 1.61, p <
0.001) compared with patients prescribed other anti-
psychotic LAIs (n = 851). However, after the index
date, the association between paliperidone palmitate
and the number of inpatient days or hospital admis-
sions was no longer signiﬁcant, compared with other
antipsychotic LAIs (Table 3).
Audit of prescribers
Around 80 psychiatrists providing care to patients
with schizophrenia in the community and in psychi-
atric hospitals were invited to respond to the survey.
Thirty-one responses were received. The most fre-
quently prescribed LAIs (Supplementary Material:
eFig. 1) were paliperidone palmitate (87.1%), zuclo-
penthixol decanoate (80.6%) and ﬂupentixol decanoate
(58.1%). In response to which LAI the psychiatrists
would choose to receive themselves (eFig. 2), paliperi-
done palmitate (25.0%) and aripiprazole (32.1%) were
the most popular. Twenty-three out of 31 psychiatrists
(74.2%) felt that if paliperidone LAI were no longer
available to prescribe, this would this be a bad thing.
Free text comments (Supplementary Material)
highlighted concerns regarding side effects of
ﬁrst-generation antipsychotic LAIs such as haloperi-
dol, ease of administration of paliperidone palmitate
via the deltoid route, and monthly (rather than 2
weekly) frequency of administration as a beneﬁt of
paliperidone palmitate.
Discussion
Since its launch in 2011, paliperidone palmitate has
rapidly become one the most frequently prescribed
LAI antipsychotics for the treatment of psychotic disor-
ders, despite a lack of clear evidence from clinical trials
that it is more effective than existing LAI antipsycho-
tics. The aim of the present study was to compare its
effectiveness to other LAIs in a large clinical sample
of patients. Our main ﬁndings were that paliperidone
palmitate was more likely to be used in patients who
had relatively high numbers of hospital admissions
and inpatient days in the previous year, and who
had been inpatients when the treatment was started.
One explanation for the greater proportion of patients
starting paliperidone palmitate as an inpatient could
be that inpatient admission reﬂects a recent deterior-
ation in mental state (possibly due to poor oral medica-
tion adherence) which leads to clinicians starting a LAI
antipsychotic (Ascher-Svanum et al. 2009).
In contrast, there was no association with increased
admissions and inpatient days in the 3 years after start-
ing paliperidone palmitate. This could be explained by
three possible mechanisms. First, because the patients
who were prescribed paliperidone palmitate had fea-
tures associated with a relatively poor prognosis, pali-
peridone palmitate might be more effective than other
LAI antipsychotics. However, another possibility is
that the severity of illness in the sample regresses toward
the mean, such that patients who were ill enough to
require the prescription of a newLAIwould in following
years be less likely to require hospitalization. As those
prescribed paliperidone palmitate had the most
inpatient days before admission, they might therefore
require relatively less hospitalization in subsequent
years. Finally, there is evidence that the acute effect of
oral antipsychotics is greatest in patients who are
severely unwell (Furukawa et al. 2015), so the improve-
ment seenwith paliperidonemaybe related to the sever-
ity of illness in these patients, rather than the effect of
paliperidone per se.
Table 1. Prevalence of Antipsychotic LAI prescribing (n = 1281).
Antipsychotic LAI
Number
in sample Percentage (%)
Paliperidone palmitate 430 33.6
Zuclopenthixol decanoate 226 17.6
Flupentixol decanoate 203 15.9
Risperidone 160 12.5
Pipotiazine palmitate 114 8.9
Haloperidol 71 5.5
Fluphenazine decanoate 36 2.8
Aripiprazole 27 2.1
Olanzapine embonate 14 1.1
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Table 2. Binary logistic regression analysis of factors associated with starting paliperidone palmitate compared with other antipsychotic LAI, n = 1281
Factor Group
Number
in sample
Percentage started on
paliperidone palmitate (%)
Unadjusted
odds ratio
95% conﬁdence
interval, p value
aAdjusted
odds ratio
95% conﬁdence
interval, p value
Age Age 16–25 years 243 33.7 0.95 0.67–1.34, p = 0.75 0.99 0.68–1.45, p = 0.97
26–35 337 35.0 Reference Reference
36–45 301 30.9 0.83 0.60–1.16, p = 0.27 0.79 0.55–1.13, p = 0.20
46–55 280 36.4 1.06 0.76–1.48, p = 0.72 0.98 0.69–1.41, p = 0.92
56–65 120 29.2 0.76 0.49–1.20, p = 0.24 0.71 0.43–1.19, p = 0.20
Gender Female 513 37.6 1.35 1.07–1.71, p = 0.01 1.37 1.04–1.79, p = 0.02
Male 768 30.9 Reference Reference
Ethnicity White 501 28.9 0.67 0.52–0.86, p = 0.002 1.06 0.79–1.41, p = 0.71
Asian 71 33.8 0.84 0.50–1.41, p = 0.51 1.27 0.72–2.23, p = 0.41
Black 597 37.9 Reference Reference
Other ethnic group 112 31.3 0.75 0.48–1.15, p = 0.18 1.04 0.64–1.67, p = 0.88
Marital status Married/cohabiting 129 41.1 1.38 0.95–2.01, p = 0.09 1.34 0.89–2.03, p = 0.16
Divorced/separated 121 38.8 1.26 0.85–1.86, p = 0.25 1.19 0.77–1.84, p = 0.43
Single 960 33.5 Reference Reference
Widowed 13 7.7 0.17 0.02–1.28, p = 0.08 0.19 0.02–1.59, p = 0.13
Marital status unknown 58 12.1 0.27 0.12–0.61, p = 0.001 0.73 0.31–1.75, p = 0.48
Diagnosis Schizophrenia and related 743 37.8 Reference Reference
Schizoaffective 77 40.3 1.11 0.69–1.79, p = 0.68 0.89 0.54–1.49, p = 0.67
Bipolar disorder 27 44.4 1.32 0.61–2.85, p = 0.49 1.13 0.49–2.62, p = 0.78
Psychotic Depression 84 26.2 0.58 0.35–0.97, p = 0.04 0.61 0.35–1.04, p = 0.07
Drug-induced psychosis 15 53.3 1.88 0.67–5.24, p = 0.23 1.88 0.63–5.62, p = 0.26
Other psychosis 335 22.7 0.48 0.36–0.65, p < 0.001 0.54 0.39–0.74, p < 0.001
Location Inpatient 694 42.9 Reference Reference
Outpatient 587 22.5 0.39 0.30–0.49, p < 0001 0.45 0.34–0.60, p < 0.001
a Adjusted for age, gender, ethnicity, marital status, diagnosis, location of starting LAI, number of admissions in the 3 years prior to starting LAI, and borough of residence.
Is
paliperidone
palm
itate
m
ore
effective
than
other
LA
I
antipsychotics?
5
https://w
w
w
.cam
bridge.org/core/term
s. https://doi.org/10.1017/S0033291717003051
D
ow
nloaded from
 https://w
w
w
.cam
bridge.org/core. King's C
ollege London, on 30 O
ct 2017 at 10:18:10, subject to the C
am
bridge C
ore term
s of use, available at
Data from four RCTs studying over 3000 patients do
not suggest that the efﬁcacy of paliperidone palmitate
is greater than that of other LAIs (Li et al. 2011;
Pandina et al. 2011; Fleischhacker et al. 2012; McEvoy
et al. 2014). Of the three trials comparing paliperidone
palmitate with risperidone LAI, one found paliperi-
done palmitate to be inferior. However, this trial
used a sub-optimal dosing regimen which did not
Fig. 1. Mean number of days spent in a psychiatric hospital before and after starting Antipsychotic LAI.
Fig. 2. Mean number of admissions to a psychiatric hospital before and after starting Antipsychotic LAI.
6 R. Patel et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291717003051
Downloaded from https://www.cambridge.org/core. King's College London, on 30 Oct 2017 at 10:18:10, subject to the Cambridge Core terms of use, available at
achieve therapeutically effective plasma levels of pali-
peridone (Fleischhacker et al. 2012). However, a study
comparing paliperidone palmitate with aripiprazole
once-monthly LAI found that aripiprazole was asso-
ciated with better health-related quality of life and
reduced rates of discontinuation compared to paliper-
idone palmitate (Naber et al. 2015). The clinical utility
of antipsychotic LAIs is not solely a function of their
effectiveness: it is also dependent on their adverse
effects and how well patients tolerate the treatment.
The survey of clinicians from the same mental health
service indicated that they are aware of the relatively
high cost of paliperidone palmitate, but prescribe it
because they perceive it as being better tolerated by
patients than other LAI antipsychotics. This is sup-
ported by recent ﬁndings indicating that discontinu-
ation rates of paliperidone LAI are lower than the
LAI preparations of risperidone, haloperidol and olan-
zapine (Decuypere et al. 2017). Furthermore, a
3-monthly preparation of paliperidone palmitate has
recently been introduced and been shown to be
equivalent in efﬁcacy to the once-monthly preparation
(Savitz et al. 2016). The reduced frequency of adminis-
tration of the 3-monthly preparation may improve tol-
erability and could be an important factor in
determining which LAI antipsychotic to prescribe.
With respect to effectiveness, the results of the pre-
sent study are consistent with those from previous
observational studies. In patients who switched from
LAI risperidone to either paliperidone palmitate or
another oral antipsychotic (Voss et al. 2015), the risk
of relapse was lower [HR 0.54 (CI 0.32–0.92)] in those
who switched to paliperidone. In another study, new
prescription of paliperidone palmitate was associated
with a reduction in admission and inpatients days
compared with previous years (Taylor & Oloﬁnjana,
2014). Decisions about the choice of LAI antipsychotic
treatment may also involve an evaluation of cost-
effectiveness. This is a particular issue with paliperi-
done palmitate in view of its high cost relative to
other LAIs (Healthand Social Care Information
Centre, 2005). Despite this, health economic studies,
sponsored by the manufacturer, suggest that the add-
itional cost of paliperidone palmitate compared to
other antipsychotic treatments is outweighed by sav-
ings in healthcare and criminal justice system costs
(Mehnert et al. 2012; Zeidler et al. 2013; Muser et al.
2015).
The main strength of this study is its large sample
size and its generalizability to clinical practice.
Capturing data from over 1200 patients prescribed
LAIs, it is well powered and allows for comparison
between most commonly prescribed LAI antipsycho-
tics. We were able to compare outcomes between
nine LAI antipsychotics approved by the BritishTa
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National Formulary, with data from over 100 patients
for ﬁve of them, which would not be feasible in a con-
ventional interventional study. Furthermore, we
obtained data on clinicians’ perspectives with respect
to antipsychotic LAI prescribing which provided a
unique insight into perceptions of efﬁcacy and toler-
ability, which would not have been possible to obtain
from EHR data alone.
The data in the present study were not controlled, as
they would be in a randomized trial. On the other
hand, the sample was more representative of the popu-
lation of patients that are seen in routine clinical prac-
tice that would have been the case in a typical clinical
trial, the sample size was larger, and duration of
follow-up was longer. However, it should be noted
that although the follow-up period in the present
study was up to 3 years, rates of discontinuation for
paliperidone palmitate have been shown to be 35%
after 1 year(Attard et al. 2014) and up to 84% for risper-
idone LAI after 3 years (Taylor et al. 2009). For this rea-
son, a number of patients may have switched to an
alternative antipsychotic or stopped receiving any anti-
psychotic therapy during the follow-up period. A fur-
ther limitation was the lack of data on psychotropic
prescribing prior to initiating a LAI antipsychotic as
these data were not comprehensively documented in
the EHR. The failure of previous antipsychotic therapy
due to poor efﬁcacy or poor treatment adherence may
have explained the greater number of inpatient days
and hospital admissions observed in patients prior to
starting paliperidone palmitate.
In conclusion, this study suggests that paliperidone
palmitate was at least as effective as other LAI antipsy-
chotics. A key issue to address in future studies is
whether paliperidone is more effective than other
LAIs when given to patients who are matched for ill-
ness severity and prognosis.
Supplementary Material
The supplementary material for this article can be
found at https://doi.org/10.1017/S0033291717003051
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